Possible Biomarkers and Therapeutic Targets for the Management of Cervical Cancer

(E-pub Ahead of Print)

Author(s): Sombeer Sharma* , Aakash Deep , A C Rana , Monu Yadav .

Journal Name: Current Cancer Therapy Reviews

Become EABM
Become Reviewer


Introduction: Cervical cancer is the most prevalent cancer in the world due to unusual extension of cervical cell. Cervical cancer occurs due to exposure of HPV (Human papillomavirus). According to WHO, it is the 4th most ordinary cancer in women. In 2018, approx 6.6% of population affected around the world and 570,000 new cases seen. In low and middle income countries 90% of cervical cancer deaths occur.

Methods: Despite various targets that cause cervical cancer including exposure of HPV, dysregulation of CASPASE enzyme, elevated expression of IAPs (Inhibitor apoptotic protein), E6 and E7 gene of HPV, inhibition of p53, BAK, p16 upregulation, CDK-inactivation cause cervical cancer, role of VEGF in cervical cancer, role of estrogen and its receptor in cervical cancer.

Conclusion: Cervical cancer can be screened by Pep test. There are various therapy can be used to treat the cervical cancer, although these therapy having various side effects so whole world move to herbal formulation to treat the cervical cancer. In this study we will discuss about cervical cancer, their cause, symptoms, pathophysiology and treatments.

Keywords: Cervical cancer, Pathphysiology. Possible treatments

Rights & PermissionsPrintExport Cite as

Article Details

(E-pub Ahead of Print)
DOI: 10.2174/1573394715666190126142508

Article Metrics

PDF: 1